Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Other Operating Expenses (2024 - 2025)

Foghorn Therapeutics has reported Other Operating Expenses over the past 2 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $4.3 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $4.3 million (up 78.57% YoY), and the annual figure for FY2025 was $4.3 million, up 78.57%.
  • Other Operating Expenses for Q4 2025 was $4.3 million at Foghorn Therapeutics, up from $2.4 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for FHTX hit a ceiling of $4.3 million in Q4 2025 and a floor of $2.4 million in Q2 2024.